| Incidence of discordant temporal artery biopsy in the diagnosis of giant cell arteritis B Durling, A Toren, V Patel, S Gilberg, E Weis, D Jordan Canadian Journal of Ophthalmology 49 (2), 157-161, 2014 | 52 | 2014 |
| Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN‐003/MYX. 1 single arm phase II … CP Venner, R LeBlanc, I Sandhu, D White, AR Belch, DE Reece, C Chen, ... American Journal of Hematology 96 (5), 552-560, 2021 | 13 | 2021 |
| Drug-induced thrombotic microangiopathy with concurrent proteasome inhibitor use in the treatment of multiple myeloma: a case series and review of the literature BE Monteith, CP Venner, DE Reece, AK Kew, M Lalancette, JS Garland, ... Clinical Lymphoma Myeloma and Leukemia 20 (11), e791-e800, 2020 | 12 | 2020 |
| Outcomes of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) vs. classical Hodgkin lymphoma (cHL) at Princess Margaret Cancer Centre J Ames, M Maganti, BE Monteith, DC Hodgson, V Kukreti, JG Kuruvilla, ... Blood 126 (23), 3863, 2015 | 8 | 2015 |
| Management of multiple myeloma: a review for general practitioners in oncology BE Monteith, I Sandhu, AS Lee Current Oncology 30 (5), 4382-4401, 2023 | 5 | 2023 |
| Overall and progression free survival from the Mcrn-003/Myx. 1 trial: a single arm phase II study of high-dose weekly carfilzomib plus cyclophosphamide and dexamethasone in the … CP Venner, R Leblanc, I Sandhu, DJ White, A Belch, DE Reece, CI Chen, ... Blood 134, 1871, 2019 | 4 | 2019 |
| Unusual carfilzomib toxicity: three cases of drug-induced thrombotic microangiopathy (TMA) after treatment with high-dose weekly carfilzomib, cyclophosphamide, and … B Monteith, C Venner, D Reece, A Kew, M Lalancette, J Garland, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e272-e273, 2019 | 4 | 2019 |
| Limited stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): A subgroup analysis of the HD. 6 clinical trial. B Monteith, EC DiMaria, M Crump, JB Ames, JN Winter, M Djurfeldt, ... Journal of Clinical Oncology 36 (15_suppl), 7535-7535, 2018 | 4 | 2018 |
| A scoping review of alternative anticoagulation strategies for hemodialysis patients with a mechanical heart valve BKA Thomson, NG Pilkey, B Monteith, RM Holden American Journal of Nephrology 52 (10-11), 861-870, 2021 | 1 | 2021 |
| A descriptive cost‐analysis of MYX. 1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory … BE Monteith, CP Venner, MC Cheung, J Pater, L Shepherd, H Richardson, ... European Journal of Haematology 107 (3), 333-342, 2021 | | 2021 |
| High-Dose Weekly Carfilzomib, Cyclophosphamide, and Dexamethasone in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma–Exploring the Financial Cost and … BE Monteith Queen's University (Canada), 2021 | | 2021 |
| Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience BE Monteith, E Masih-Khan, EG Atenafu, C Chen, A Prica, D Reece, ... Blood 126 (23), 5361, 2015 | | 2015 |
| CLINICAL OUTCOMES OF PATIENTS WHO DEVELOP CARDIOGENIC SHOCK (CS) AFTER AN ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) WITHIN A DEDICATED CITYWIDE PRIMARY PERCUTANEOUS CORONARY … BE Durling, MR Le May, DY So, MP V, Fröeschl, ER O'Brien, M Labinaz, ... Journal of the American College of Cardiology 57 (14S), E1031-E1031, 2011 | | 2011 |
| SHORT-AND LONG-TERM OUTCOMES OF SYSTEMATIC PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WHO DEVELOP CARDIOGENIC SHOCK AFTER A ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) BE Durling, MR Le May, DY So, MPV Frö; eschl, ER O’Brien, M Labinaz, ... Journal of the American College of Cardiology 55 (10S), A105. E982-A105. E982, 2010 | | 2010 |
